journal article·2012-08-28

Selenium Nanoparticles as a Carrier of 5-Fluorouracil to Achieve Anticancer Synergism

Wen Liu, Xiaoling Li, Yum-Shing Wong, Wenjie Zheng, Yibo Zhang, Wenqiang Cao, Tianfeng Chen

ACS Nano· Volume 6· Issue 8
Publisher page

Abstract

A simple method for preparing 5-fluorouracil surface-functionalized selenium nanoparticles (5FU-SeNPs) with enhanced anticancer activity has been demonstrated in the present study. Spherical SeNPs were capped with 5FU through formation of Se-O and Se-N bonds and physical adsorption, leading to the stable structure of the conjugates. 5FU surface decoration significantly enhanced the cellular uptake of SeNPs through endocytosis. A panel of five human cancer cell lines was shown to be susceptible to 5FU-SeNPs, with IC(50) values ranging from 6.2 to 14.4 μM. Despite this potency, 5FU-SeNP possesses great selectivity between cancer and normal cells. Induction of apoptosis in A375 human melanoma cells by 5FU-SeNPs was evidenced by accumulation of sub-G1 cell population, DNA fragmentation, and nuclear condensation. The contribution of the intrinsic apoptotic pathway to the cell apoptosis was confirmed by activation of caspase-9 and depletion of mitochondrial membrane potential. Pretreatment of cells with a general caspase inhibitor z-VAD-fmk significantly prevented 5FU-SeNP-induced apoptosis, indicating that 5FU-SeNP induced caspase-dependent apoptosis in A375 cells. Furthermore, 5FU-SeNP-induced apoptosis was found dependent on ROS generation. Our results suggest that the strategy to use SeNPs as a carrier of 5FU could be a highly efficient way to achieve anticancer synergism. 5FU-SeNPs may be a candidate for further evaluation as a chemopreventive and chemotherapeutic agent for human cancers, especially melanoma.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Selenium in Biological Systems · Fullerene Chemistry and Applications · Carbon and Quantum Dots Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Jinan University, Guangzhou 510632, China

School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China

References (46)

Show source-provided references
1. Ferlay J. · Int. J. Cancer · 2010 · 127 · 289310.1002/ijc.25516 ↗
2. Yager P. · Nature · 2006 · 442 · 41210.1038/nature05064 ↗
3. Peer D. · Nat. Nanotechnol · 2007 · 2 · 75110.1038/nnano.2007.387 ↗
4. Farokhzad O. C. · ACS Nano · 2009 · 3 · 1610.1021/nn900002m ↗
5. Popova N. V. · Cancer Lett. · 2002 · 179 · 3910.1016/S0304-3835(01)00862-X ↗
6. Redman C. · Cancer Lett. · 1998 · 125 · 10310.1016/S0304-3835(97)00497-7 ↗
7. Prokopczyk B. · Cancer Lett. · 2000 · 161 · 3510.1016/S0304-3835(00)00590-5 ↗
8. Hu H. · Clin. Cancer Res. · 2008 · 14 · 115010.1158/1078-0432.CCR-07-4037 ↗
9. Li S. · Mol. Cancer Ther. · 2007 · 6 · 103110.1158/1535-7163.MCT-06-0643 ↗
10. Yang G. Q. · Biomed. Environ. Sci. · 1995 · 8 · 187
11. Reid M. E. · J. Trace Elem. Med. Biol. · 2004 · 18 · 6910.1016/j.jtemb.2004.03.004 ↗
12. Wang H. · Free Radic. Biol. Med. · 2007 · 42 · 152410.1016/j.freeradbiomed.2007.02.013 ↗
13. Zhang J. · Toxicol. Sci. · 2008 · 101 · 2210.1093/toxsci/kfm221 ↗
14. Park K. · Adv. Funct. Mater. · 2009 · 19 · 155310.1002/adfm.200801655 ↗
15. Cao S. · Clin. Cancer Res. · 2004 · 10 · 256110.1158/1078-0432.CCR-03-0268 ↗
16. Card J. W. · Int. J. Toxicol. · 2010 · 29 · 40210.1177/1091581810370720 ↗
17. Zhang J. · Life Sci. · 2005 · 76 · 109910.1016/j.lfs.2004.08.015 ↗
18. Takimoto C. H. · Clin. Cancer Res. · 2007 · 13 · 483210.1158/1078-0432.CCR-07-0475 ↗
19. Martenson J. A. · Int. J. Radiat. Oncol. Biol. Phys. · 1996 · 35 · 74510.1016/0360-3016(96)00146-0 ↗
20. Saif M. W. · Anticancer Drugs · 2006 · 17 · 109510.1097/01.cad.0000231479.30524.0e ↗
21. Boyer J. · Anticancer Res. · 2004 · 24 · 417
22. Kamoshida S. · Acta Histochem. Cytochem. · 2003 · 36 · 47110.1267/ahc.36.471 ↗
23. Visser G. W. · Cancer Chemother. Pharmacol. · 1990 · 26 · 20510.1007/BF02897200 ↗
24. Thant A. A. · Anticancer Res. · 2008 · 28 · 3579
25. Schroeder C. P. · Biol. Trace Elem. Res. · 2004 · 99 · 1710.1385/BTER:99:1-3:017 ↗
26. Fakih M. · Clin. Colorectal Cancer · 2005 · 5 · 13210.3816/CCC.2005.n.026 ↗
27. Kaur G. · J. Phys. Chem. C · 2009 · 113 · 1367010.1021/jp903685g ↗
28. Li Q. · Mater. Lett. · 2010 · 64 · 61410.1016/j.matlet.2009.12.019 ↗
29. Villanueva A. · J. Phy. Chem. C · 2010 · 114 · 197610.1021/jp907046f ↗
30. Acharya S. · Biomaterials · 2009 · 30 · 573710.1016/j.biomaterials.2009.07.008 ↗
31. Chauhan A. · PLoS One · 2012 · 7 · e3204910.1371/journal.pone.0032049 ↗
32. Lozan V. · Dalton Trans. · 2007 · 451110.1039/b709890a ↗
33. McAuley B. · Anal. Chim. Acta · 2007 · 581 · 30910.1016/j.aca.2006.08.023 ↗
34. Wohlhueter RM M. R. · J. Cell Physiol. · 1980 · 104 · 30910.1002/jcp.1041040305 ↗
35. Yamamoto S. · J. Biochem. · 1981 · 90 · 63510.1093/oxfordjournals.jbchem.a133517 ↗
36. Ojugo A. S. · Br. J. Cancer. · 1998 · 77 · 87310.1038/bjc.1998.144 ↗
37. Wang F. · ACS Nano · 2011 · 5 · 367910.1021/nn200007z ↗
38. Imani M. · AAPS PharmSciTech · 2010 · 11 · 126810.1208/s12249-010-9494-9 ↗
39. Tallarida R. J. · J. Pharmacol. Exp. Ther. · 2001 · 298 · 86510.1016/S0022-3565(24)29450-7 ↗
40. Sinha R. · Curr. Cancer Drug Targets · 2004 · 4 · 1310.2174/1568009043481614 ↗
41. Van Gurp M. · Biochem. Biophys. Res. Commun. · 2003 · 304 · 48710.1016/S0006-291X(03)00621-1 ↗
42. Ghobrial I. M. · CA Cancer J. Clin. · 2005 · 55 · 17810.3322/canjclin.55.3.178 ↗
43. Fulda S. · Oncogene · 2006 · 25 · 479810.1038/sj.onc.1209608 ↗
44. Dhanasekaran A. · Free Radic. Biol. Med. · 2005 · 39 · 56710.1016/j.freeradbiomed.2005.04.016 ↗
45. Apel K. · Annu. Rev. Plant. Biol. · 2004 · 55 · 37310.1146/annurev.arplant.55.031903.141701 ↗
46. Chen T. · Biomed. Pharmacother. · 2009 · 63 · 10510.1016/j.biopha.2008.03.009 ↗